GERMANTOWN, Md., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced poster presentations at two upcoming scientific conferences. Presentations include preclinical data in both of the company’s stem cell and small molecule platforms at the Society for Neurosciences Annual Meeting, as well as the American College of Toxicology Annual Meeting.
Following is a schedule of relevant presentations:
2016 American College of Toxicology Annual Meeting
Title: “Comprehensive In Vivo Nonclinical Safety Assessment of NSI-189, a Small Molecule New Chemical Entity for the Treatment of Major Depressive Disorder”
Date: Monday, November 7
Time: 5:30-7 PM EST
Presenter: Grace Furman, PhD, CEO Paracelsus, Inc
Location: Baltimore Marriott Waterfront, Baltimore, MD
2016 Society for Neurosciences Annual Meeting
Title: "NSI-189, a neurogenic compound enhances short-term and long-term potentiation in C57BL/6 mice and reverses LTP impairment in a mouse model of Angelman Syndrome”
Date: Sunday, November 13
Time: 1-5 PM PT
Presenter: Michel Baudry, PhD, Graduate College of Biomedical Sciences, Western University of Health
Location: San Diego Convention Center (San Diego, CA)
Title: “Durable engraftment, neuronal differentiation of human fetal neural stem cell transplants in penetrating ballistic-like brain injury accompanied by amelioration of cognitive deficits.”
Date: Monday, November 14
Time: 8AM-12PM PT
Presenter: Shyam Gajavelli, PhD, University of Miami
Location: San Diego Convention Center (San Diego, CA)
Title: “Induction of immune tolerance by short-course immunosuppression after spinal grafting of allogeneic neural precursors in pigs with previous chronic spinal cord traumatic injury”
Date: Monday, November 14
Time: 8AM-12PM PT
Presenter: Martin Marsala, MD, University of San Diego School of Medicine
Location: San Diego Convention Center (San Diego, CA)
Title: “Remyelinating human oligodendrocyte progenitors for regenerative treatment of demyelinating diseases and spinal cord injury”
Date: Wed, November 16
Time: 8AM-12PM PT
Presenter: Tom Hazel, PhD, VP of Research, Neuralstem, Inc.
Location: San Diego Convention Center (San Diego, CA)
About Neuralstem
Neuralstem's patented technology enables the commercial-scale production of multiple types of central nervous system stem cells, which are being developed as potential therapies for multiple central nervous system diseases and conditions.
Neuralstem’s technology enables the generation of small molecule compounds by screening hippocampal stem cell lines with its proprietary systematic chemical screening process. The screening process has led to the discovery and patenting of molecules that Neuralstem believes may stimulate the brain's capacity to generate new neurons, potentially reversing pathophysiologies associated with certain central nervous system (CNS) conditions.
The company has completed Phase 1a and 1b trials evaluating NSI-189, a novel neurogenic small molecule product candidate, for the treatment of major depressive disorder or MDD, and is currently conducting a Phase 2 efficacy study for MDD.
Neuralstem's stem cell therapy product candidate, NSI-566, is a spinal cord-derived neural stem cell line. Neuralstem is currently evaluating NSI-566 in three indications: stroke, chronic spinal cord injury (cSCI), and Amyotrophic Lateral Sclerosis (ALS).
Neuralstem is conducting a Phase 1 safety study for the treatment of paralysis from chronic motor stroke at the BaYi Brain Hospital in Beijing, China. In addition, NSI-566 was evaluated in a Phase 1 safety study to treat paralysis due to chronic spinal cord injury, as well as, a Phase 1 and Phase 2a risk escalation, safety trials for ALS. Patients from all three indications are currently in long-term observational follow-up periods to continue to monitor safety and possible therapeutic benefits.
Cautionary Statement Regarding Forward Looking Information:
This news release contains "forward-looking statements" made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "seek" or "will." Forward-looking statements by their nature address matters that are, to different degrees, uncertain.
Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the Annual Report on Form 10-K for the year ended December 31, 2015, and filed with the Securities and Exchange Commission (SEC) on March 14, 2016, Form 10-Q for the period ended June 30, 2016, and in other reports filed with the SEC.